Recent years have witnessed the continuous clinical feasibility and increasing commercial value of antibody-drug conjugates (ADCs). As a result, many research institutions attempt to connect PROTAC with a monoclonal antibody (mAb) by imitating the design principle of ADC to improve the delivery efficiency of PROTAC in vivo. This combination is called degrader-antibody conjugates (DACs), which...